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Large genotype–phenotype study 
in carriers of D4Z4 borderline 
alleles provides guidance 
for facioscapulohumeral muscular 
dystrophy diagnosis
Giulia Ricci1,2,22, Fabiano Mele1,22, Monica Govi1, Lucia Ruggiero3, Francesco Sera4, 
Liliana Vercelli5, Cinzia Bettio6,7, Lucio Santoro3, Tiziana Mongini5, Luisa Villa8, 
Maurizio Moggio8, Massimiliano Filosto9, Marina Scarlato10, Stefano C. Previtali10, 
Silvia Maria Tripodi11, Elena Pegoraro11, Roberta Telese12, Antonio Di Muzio12, 
Carmelo Rodolico13, Elisabetta Bucci14, Giovanni Antonini14, Maria Grazia D’Angelo15, 
Angela Berardinelli16, Lorenzo Maggi17, Rachele Piras18, Maria Antonietta Maioli18, 
Gabriele Siciliano2, Giuliano Tomelleri6,7, Corrado Angelini19 & Rossella Tupler1,6,7,20,21*
Facioscapulohumeral muscular dystrophy (FSHD) is a myopathy with prevalence of 1 in 20,000. Almost 
all patients affected by FSHD carry deletions of an integral number of tandem 3.3 kilobase repeats, 
termed D4Z4, located on chromosome 4q35. Assessment of size of D4Z4 alleles is commonly used 
for FSHD diagnosis. However, the extended molecular testing has expanded the spectrum of clinical 
phenotypes. In particular, D4Z4 alleles with 9–10 repeat have been found in healthy individuals, in 
subjects with FSHD or affected by other myopathies. These findings weakened the strict relationship 
between observed phenotypes and their underlying genotypes, complicating the interpretation 
of molecular findings for diagnosis and genetic counseling. In light of the wide clinical variability 
detected in carriers of D4Z4 alleles with 9–10 repeats, we applied a standardized methodology, the 
Comprehensive Clinical Evaluation Form (CCEF), to describe and characterize the phenotype of 244 
individuals carrying D4Z4 alleles with 9–10 repeats (134 index cases and 110 relatives). The study 
shows that 54.5% of index cases display a classical FSHD phenotype with typical facial and scapular 
muscle weakness, whereas 20.1% present incomplete phenotype with facial weakness or scapular 
girdle weakness, 6.7% display minor signs such as winged scapula or hyperCKemia, without functional 
OPEN
1Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy. 2Department of Clinical 
and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy. 3Department of Neurosciences, 
Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy. 4Department of 
Statistics, Computer Science and Applications “G. Parenti”, University of Florence, Florence, Italy. 5Department 
of Neuroscience, Center for Neuromuscular Diseases, University of Turin, Turin, Italy. 6Department of Biomedical, 
Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via G. Campi 287, 41125 Modena, 
Italy. 7Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, 
Italy. 8Neuromuscular Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari 
Center, University of Milan, Milan, Italy. 9Neurology Clinic, Spedali Civili Hospital, Brescia, Italy. 10INSPE and 
Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy. 11Department of Neurosciences, 
University of Padua, Padua, Italy. 12Center for Neuromuscular Disease, CeSI, University “G. D’Annunzio”, Chieti, 
Italy. 13Department of Neurosciences, Policlinico “G. Martino”, University of Messina, Messina, Italy. 14Department 
of Neuroscience, Mental Health and Sensory Organs, S. Andrea Hospital, University of Rome “La Sapienza”, Rome, 
Italy. 15Department of Neurorehabilitation, IRCCS Eugenio Medea, Bosisio Parini, Italy. 16Unit of Child Neurology 
and Psychiatry, IRCCS “C. Mondino” Foundation, Pavia, Italy. 17IRCCS Foundation, C. Besta Neurological Institute, 
Milan, Italy. 18ASL8, Centro Sclerosi Multipla, Cagliari, Italy. 19IRCCS San Camillo, Venice, Italy. 20Department 
of Molecular Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, USA. 21Li Weibo 
Institute for Rare Diseases Research at the University of Massachusetts Medical School, Worcester, USA. 22These 
authors contributed equally: Giulia Ricci and Fabiano Mele. *email: rossella.tupler@unimore.it
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21648  | https://doi.org/10.1038/s41598-020-78578-7
www.nature.com/scientificreports/
motor impairment, and 18.7% of index cases show more complex phenotypes with atypical clinical 
features. Family studies revealed that 70.9% of relatives carrying 9–10 D4Z4 reduced alleles has no 
motor impairment, whereas a few relatives (10.0%) display a classical FSHD phenotype. Importantly 
all relatives of index cases with no FSHD phenotype were healthy carriers. These data establish 
the low penetrance of D4Z4 alleles with 9–10 repeats. We recommend the use of CCEF for the 
standardized clinical assessment integrated by family studies and further molecular investigation for 
appropriate diagnosis and genetic counseling. Especially in presence of atypical phenotypes and/or 
sporadic cases with all healthy relatives is not possible to perform conclusive diagnosis of FSHD, but 
all these cases need further studies for a proper diagnosis, to search novel causative genetic defects or 
investigate environmental factors or co-morbidities that may trigger the pathogenic process. These 
evidences are also fundamental for the stratification of patients eligible for clinical trials. Our work 
reinforces the value of large genotype–phenotype studies to define criteria for clinical practice and 
genetic counseling in rare diseases.
Abbreviations
FSHD  Facioscapulohumeral muscular dystrophy
FSHD1 and FSHD2  Facioscapulohumeral muscular dystrophy type 1 and type 2
CCEF  Comprehensive Clinical Evaluation Form
DRA  D4Z4 reduced alleles
bDRA  Borderline D4Z4 reduced alleles
INRF  Italian National Registry for FSHD
SMCHD1  Structural maintenance of chromosomes flexible hinge domain containing 1
DNMT3B  DNA methyltransferase 3 beta
Facioscapulohumeral muscular dystrophy (FSHD, OMIM #158900) has prevalence of one in 8–20,0001,2. The 
disease is characterized by a peculiar distribution of muscle weakness affecting facial and shoulder girdle mus-
cles. Abdominal muscles also become affected, leading to a characteristic hyperlordotic posture. The selective 
and precocious weakness of tibialis anterior muscle is typical at lower limb, eventually followed by proximal leg 
muscles  involvement3,4.
Presently, FSHD diagnosis is based on molecular  findings5. Two genetically distinct disease subtypes, FSHD1 
and FSHD2, have been described up to  now6. FSHD1 is associated with contractions of a polymorphic macrosat-
ellite repeat on chromosome 4q35.27. This region consists of tandemly arrayed 3.3 kb D4Z4 repeat elements rang-
ing from 11 to > 100 repeat units in healthy subjects. Individuals displaying FSHD symptoms and carrying D4Z4 
alleles with 10 or fewer repeat units are genetically defined as  FSHD18. They represent 95% of people with FSHD.
FSHD2 defines 5–10% of affected individuals carrying two D4Z4 arrays in the healthy range (> 10 repeat 
units). FSHD2 is defined as the cause of SMCHD1 mutation in OMIM and Gene Table (http://www.muscl egene 
table .fr). FSHD1 and FSHD2, considered clinically undistinguishable, are characterized by DNA hypomethyla-
tion of the 4q35 D4Z4  array9.
FSHD is characterized by reduced penetrance and wide variability in the clinical expression among patients 
and within  families10–13. Indeed, the widespread use of molecular analysis to diagnose FSHD has revealed various 
phenotypes in subjects carrying D4Z4 alleles of reduced size, including atypical or incomplete  phenotypes12–19. 
Furthermore, it has been observed that in the general population 3% of people carry D4Z4 array in the FSHD 
size  range20–22. All this makes genotype–phenotype association difficult and hinders proper diagnosis, especially 
in presence of atypical clinical  presentation13. Molecular factors such as level of D4Z4 methylation or mutations 
in other genes (i.e. SMCHD1or DNMT3B genes) have been recently added to the list of possible contributors to 
disease onset and modifiers of disease severity, and also to explain a digenic inheritance for  FSHD9,23–25; even 
though more extended analysis suggest the limited contribution of these  factors26,27. This clinical and molecular 
complexity has complicated FSHD diagnosis, clinical practice and genetic counseling. Based on the above con-
siderations, how can we interpret and use the result of the FSHD molecular test?
Here, we investigate the occurrence of the FSHD classical phenotype in 134 index cases and 110 relatives 
carrying alleles with 9–10 D4Z4 repeat units from the Italian National Registry for FSHD (INRF). Alleles of 
this size, named borderline D4Z4 reduced alleles (bDRA), are considered the upper size of the diagnostic range 
and pose the major diagnostic challenges. In fact, a wide phenotypic spectrum including atypical or incomplete 
phenotypes with no affected relatives is frequently observed in subjects carrying a  bDRA28, making the defini-
tion of a clear cut-off point problematic.
Materials and methods
Study design and participants. In this study, we enrolled subjects carrying a bDRA. Index cases were 
identified through the INRF considering a 9-year time-window (2008–2016). The INRF database contains clini-
cal and molecular data of subjects examined by the Italian Clinical Network for FSHD (www.fshd.it)29. Out of 
1340 index cases bearing a DRA with 1–10 repeats, we identified 166 subjects (14.6%) carrying a bDRA (Supple-
mentary Fig. 1). Clinical and molecular analysis was extended to all available and willing to participate relatives. 
Phenotypic characterization was performed on 134 index cases and 110 relatives carrying a bDRA from 58 unre-
lated families. Seventy-six index cases did not have available relatives carrying a bDRA (Supplementary Fig 2).
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Availability of data. The dataset analyzed during the current study is available from the corresponding 
author upon request.
Procedures. We used the Comprehensive Clinical Evaluation Form (CCEF) for the clinical characteriza-
tion of each  subject30. This evaluation protocol defines the severity of the motor impairment, and generates the 
FSHD score, which translates disability into a number. It ranges from zero, when no objective evidence of muscle 
functional impairment is present, to 15, when all the muscle groups tested are severely impaired (www.fshd.
it)31. Subjects were further classified on the basis of the clinical signs considering typical and atypical features, 
as listed in the CCEF (Supplementary Fig. 3): (1) subjects presenting facial and scapular girdle muscle weakness 
typical of FSHD (category A, subcategories A1–A3), (2) subjects with muscle weakness limited to scapular girdle 
or facial muscles (category B, respectively subcategories B1 and B2), (3) asymptomatic without any functional 
motor impairment (FSHD score 0) or healthy subjects (category C, respectively subcategories C1 and C2), (4) 
subjects with myopathic phenotype presenting clinical features not consistent with FSHD canonical phenotype 
(D, subcategories D1, D2). Age at onset was estimated as self-reported anamnestic  record32.
Molecular characterization. DNA was prepared from isolated lymphocytes according to standard pro-
cedures. In brief, restriction endonuclease digestion of DNA was performed in agarose plugs with the appro-
priate restriction enzyme: EcoRI, EcoRI/BlnI. Digested DNA was separated by pulsed field gel electrophoresis 
(PFGE) in 1% agarose gels, as previously  described18. Allele sizes were estimated by Southern hybridization with 
probe p13E-11 of 7 μg of EcoRI-digested, EcoRI/BlnI-digested genomic DNA extracted from peripheral blood 
lymphocytes, electrophoresed in a 0.4% agarose gel, for 62–64 h at 35 V, alongside an 8–48 kb marker (Bio-
Rad). Participants carrying alleles of 36–41 kb (9–10 D4Z4 units) in size were included in the study. Within the 
European population, pathological D4Z4 contractions usually are associated with the permissive 4qA haplotype 
in the subtelomeric region of chromosome 4q. The qA polymorphism was assessed by HindIII digestion and 
hybridization with qA probe. Restriction fragments were detected by autoradiography or by using the Typhoon 
Trio system (GE Healthcare). To verify that the obtained shortened D4Z4 fragment on chromosome 4 has a 
causative 4qA haplotype, an additional HindIII Southern blot was performed as suggested for the molecular 
diagnosis of  FSHD133.
Statistical analysis. We used descriptive statistics for quantitative variables (mean and standard deviation) 
and qualitative variables (relative frequencies). Associations between qualitative variables were assessed using 
chi-square test or Fisher exact test. Associations between clinical parameters were described and tested using 
Pearson r correlation coefficient. Associations between quantitative variables and qualitative variables were eval-
uated using t test or ANOVA.
Ethics approval and consent to participate. The INRF database was approved by the Provincial Eth-
ics Committee of Modena (2712/CE). Informed written consent was obtained from all study participants, in 
accordance with the ethical standards of the 1964 Declaration of Helsinki.
Consent for publication. This manuscript does not contain any individual person’s data in any form. Each 
patient was identified by a unique alphanumeric identification code and all data were made anonymous.
Results
Different phenotypes of index cases carrying 9–10 DRA. The clinical characterization of 134 index 
cases carrying a bDRA (Table  1A) revealed their phenotypic heterogeneity (Fig.  1A). Seventy-three (54.5%) 
displayed the classic FSHD phenotype and were classified as category A. The remaining 61 index cases (45.5%) 
showed various phenotype: 27 presented muscle weakness limited to scapular girdle or facial muscles (20.1%), 
identified as category B, 25 subjects showing myopathic phenotypes with clinical features not consistent with 
Table 1.  Distribution of clinical categories among subjects carrying a bDRA.
CCEF category (n) Mean age at evaluation Mean age at onset Mean FSHD score
a. Index cases 134 (84 M, 50 F)
A 73 (46 M, 27 F) 57.5 ± 15.8 32.9 ± 16.0 6.8 ± 3.0
B 27 (20 M, 7 F) 51.6 ± 15.1 35.3 ± 18.2 3.0 ± 1.8
C 9 (4 M, 5 F) 33.7 ± 20.9 – –
D 25 (14 M, 11 F) 56.1 ± 13.0 38.2 ± 18.5 6.0 ± 3.4
b. Relatives 110 (56 M, 54 F)
A 11 (3 M, 8 F) 55.2 ± 19.3 32.2 ± 17.6 5.5 ± 2.8
B 15 (12 M, 3 F) 51.7 ± 19.7 35.3 ± 17.0 2.5 ± 2.1
C 78 (39 M, 39 F) 42.0 ± 16.0 – –
D 6 (2 M, 4 F) 57.0 ± 27.8 45.0 ± 36.1 5.3 ± 4.5
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FSHD (18.7%) were listed as category D, 9 subjects (6.7%) did not show motor impairment (FSHD score 0) and 
were classified as subcategory C1 for the presence of mild hyperCKemia and winged scapula.
As expected for a slowly progressive disease as FSHD, we observed that there is a correlation between the 
FSHD score and age at examination or disease duration (Pearson coefficient equal to 0.37 and 0.36 respectively) 
in all patients falling in categories A, B, or D. We therefore evaluated whether clinical categories may represent 
different stages of disease progression that is pre-symptomatic carriers are included in category C, mildly affected 
individuals are in category B and fully manifesting subjects are in category A. If this is the case one would expect 
category C subjects to be the youngest and category A the oldest. Figure 2A shows that distribution of clinical 
categories is not influenced by the age at examination.
Index cases with classic FSHD phenotype show a moderate-severe form of disease. Among 
the 73 index cases classified as category A, 2 presented severe facial weakness and were classified as subcat-
egory A1, 25 showed the classical pattern of facial weakness (subcategory A2), 46 presented mild facial involve-
ment (subcategory A3) (Fig. 1B). The mean age at onset of category A index cases was 32.9 ± 16.0, 53.4% of 
them reported disease onset after 30 years of age with the progressive development of a moderate-severe motor 
impairment (mean age at evaluation 57.5 ± 15.8, mean FSHD score 6.8 ± 3.0) (Table 1).
Figure 1.  Phenotypic characterization of index cases and relatives carrying a bDRA on the basis of the CCEF 
categories. Distribution of clinical categories (A) and subcategories (B) among index cases. Distribution of 
clinical categories (C) and subcategories (D) among relatives.
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Incomplete FSHD phenotype is associated with milder motor disability. Facial-sparing scapu-
lar myopathy is often detected in clinical practice and it must be distinguished from other forms of myopathy 
including scapular peroneal  syndrome34–36. To further investigate this aspect, we compared the degree of muscle 
impairment of subcategory B1 and category A excluding the scoring of facial muscle weakness. As shown in 
Table 2, the index cases with facial-sparing phenotype classified as subcategory B1 had comparable mean age at 
evaluation and mean age at onset of category A index cases. Instead the average FSHD score assessed in category 
B1 subjects was significantly lower than the one detected in category A subjects (3.2 ± 1.8 versus 5.6 ± 2.8, t test 
p < 0.001). Thus, subcategory B1 patients have a milder clinical phenotype.
Figure 2.  Distribution of clinical severity among subjects carrying a bDRA according to FSHD score and 
age at examination: index cases (A) and relatives (B). Clinical categories are described as follows red diamond 
(category A), yellow square (category B), green triangle (category C), blue cross (category D).
Table 2.  Index cases with typical (category A) and facial-sparing (category B1) phenotype. *p < 0.001.
CCEF category (n) Mean age at evaluation Mean age at onset FSHD score excluding facial scoring
A (73) 57.5 ± 17.8 32.9 ± 16.0 5.6 ± 2.8*
B1 (24) 51.6 ± 15.0 33.3 ± 17.1 3.2 ± 1.8*
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Three index cases, aged 31, 52 and 70 years, were classified as subcategory B2 showing facial weakness without 
scapular girdle involvement. They presented a mild motor impairment, FSHD score 1, 1, 4 respectively. Two of 
them had isolated weakness of facial muscles.
Complex/atypical phenotypes in bDRA index cases. Out of 134 index cases, 25 index cases (18.7%) 
were classified as category D. Sixteen patients were identified as subcategory D1 for the presence of additional 
atypical features, more frequently including prevalent pelvic girdle weakness and axial involvement with bent 
spine and dropped head. Nine index cases (6.7%) presented phenotypes inconsistent with FSHD, such as isolated 
axial weakness (i.e. bent spine syndrome), or other clinical conditions described in Table 3; therefore they were 
classified as subcategory D2.
There was also the case of a woman (patient 22 in Table 3) that was classified as subcategory D1 because of the 
concomitant diagnosis of myasthenia gravis associated with abnormally elevated serum levels of acetylcholine 
receptor antibodies and thymoma. She was the only one among category D index cases who reported a positive 
family history for FSHD.
To date, all the others have not received any alternative diagnosis yet.
Analysis of prognostic significance of bDRA in relatives. We clinically evaluated 110 relatives car-
rying a bDRA (56 males, 54 females, mean age at evaluation 45.4 ± 18.2) from 58 unrelated families (Table 1b, 
Fig. 1C). Among them, 78 subjects (70.9%) did not show motor impairment (mean age at evaluation 42.0 ± 16.0) 
and were classified as category C (Fig. 1C), in particular 56 (54.5%) were completely normal at neurological 
examination (subcategory C2) and 22 (16.4%) showed minor signs (winged scapula and/or horizontal clavi-
cles), without motor impairment (subcategory C1) (Fig.  1D). Eleven (10.0%) were identified as category A, 
15(13.6%) as category B, 6 (5.5%) as category D and subcategorized as shown in Fig. 1D. Figure 2B shows the 
Table 3.  Index cases with atypical clinical features (clinical category D).
Case Sex Age Age at onset Atypical phenotypic features Family history Clinical category
Other relatives with bDRA 
(category)
1 F 60 40 Axial involvement (bent syn-drome), cardiac involvement Negative D2
2 F 59 48 Pelvic limb girdle onset Negative D1 Daughter (C)
3 M 28 17 Recurrent myoglobinuria Negative D2
4 F 64 25 Pelvic limb girdle onset, LGMD-like Negative D1
5 F 66 50 Isolated pelvic girdle involve-ment Negative D2 Two sons (both C)
6 M 74 16 Dropped head Negative D1
7 M 54 43 Pelvic limb girdle onset Negative D1 Three relatives (all C)
8 F 31 0 Congenital facio-brachio-crural hemiparesis Negative D2
Mother and maternal aunt 
(both C)
9 F 64 6 Prevailing pelvic girdle involvement Negative D1
10 M 66 54 Axial involvement (bent syndrome) Negative D1 Son (C)
11 F 63 20 LGMD-like Negative D2 Brother and sister (both C)
12 M 69 55 Axial involvement Negative D2
13 M 47 39 Early gastrocnemius atrophy and weakness Negative D1
14 M 66 50 LGMD-like Negative D2
15 M 66 66 Isolated pelvic girdle involve-ment Negative D2 Two sons (both C)
16 M 61 47 Prevailing axial involvement Negative D1
17 F 49 43 LGMD-like Negative D1 Three relatives (C)
18 M 52 48 Dropped head Negative D1
19 F 54 50 Bent syndrome Negative D2
20 M 76 70 Axial involvement Negative D1
21 F 53 41 LGMD-like Positive D1
22 F 48 20 Diagnosis of myasthenia gravis Positive D1
Two sons (both C) and sister 
(A)
23 F 46 24 Prevailing pelvic girdle involvement Negative D1
24 M 28 18 Blood CPK > 4 × normal valueNo winged scapula Positive D1 Father (B)
25 M 58 54 Prevailing pelvic girdle involvement Negative D1
7
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21648  | https://doi.org/10.1038/s41598-020-78578-7
www.nature.com/scientificreports/
distribution of clinical categories among relatives according to age at examination and FSHD score. We observed 
non-penetrant carriers in all classes of age, accordingly with previous  reports12. In one family we found that the 
index case developed FSHD at 45 years of age in the period following three cycles of chemotherapy because of 
non-Hodgkin lymphoma. In this family 5 relatives carrying the 9 U DRA were healthy whereas the 92-year-old 
father received FSHD score 4 at neurological examination for limb girdle weakness, therefore classified as cat-
egory D2 (Fig. 3).
We evaluated the penetrance of bDRA in 12 families with at least 4 carriers. Table 4 summarizes our findings: 
the probands have different phenotypes. The overall penetrance of bDRA is 40%, ranging from 0 in one family, 
in which all subjects had no muscle impairment and were assessed as category C, to 100% in two families; in one 
of these two the proband was assessed as category A as well two relatives, one relative was category D2; in the 
other, the proband was category A, two relatives were assessed as category B1, one as D1.
Considerations on genetic counseling in family with bDRA. We then evaluated the distribution of 
clinical phenotypes within families. Figure 4 shows that out of 58 families, in 10 (17.2%) there was at least one 
category A relative. In these families, the proband was classified as category A, with the exception of one family 
in which the index case was considered as D1 for the co-presence of myasthenia gravis, as described above. In 36 
families (62%) all relatives were non-penetrant. In our large cohort, index cases assessed as category B did not 
have relatives that were classified as category A, instead in three families we observed only relatives of category B.
We then analyzed whether the clinical category of the index case can predict the phenotype observed in 
the relatives carrying the same bDRA. We subdivided the probands in two groups on the basis of the CCEF 
phenotype observed in their relatives. One group included 19 probands whose relatives had classical FSHD or 
incomplete phenotype (categories A and B); the other group included 39 probands whose relatives were healthy 
or had a complex phenotype (categories C and D). This analysis shows that the distribution of clinical categories 
among the 58 probands subdivided on the basis of the phenotypic categories of their relatives does not signifi-
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Figure 3.  Pedigree Family 952. Age (years) at clinical evaluation, FSHD score (sc), CCEF clinical category, 
D4Z4 molecular haplotype are reported. Individuals I.1, II.1, II.3, III.1, III.2, III.3, III.4, III.5 carry one D4Z4 
allele with 9 RU associated with the qA polymorphism. Individual II.3 developed FSHD at 45 years in the period 
following three cycles of chemotherapy.
8
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21648  | https://doi.org/10.1038/s41598-020-78578-7
www.nature.com/scientificreports/
Discussion
The present study substantiates the value of the clinical categories identified by the CCEF in response to the 
necessity of describing the different phenotypes of probands and their relatives and shows the possibility of 
stratifying clinical groups for clinical and molecular studies.
Through years molecular diagnostics in FSHD has faced several challenges mainly because of the wide clini-
cal variability observed among patients and within families, the reduced penetrance of D4Z4 reduced alleles 
and their high frequency in the general  population12,14,15,22,37–41. While there is a natural tendency to look for 
a relationship between number of repeat units and clinical severity, this approach has presented several flaws 
through years. Stratification of patients in clinical trials using the number of D4Z4 repeat units or methylation 
status has proven not to be accurate, suggesting that other disease-causing modifiers can modulate the clinical 
 outcome13,27. Up to now, studies had involved a small number of patients with a higher D4Z4 alleles  range28,40,42. 
This study selectively investigated the phenotype of the largest cohort of subjects with 9–10 D4Z4 repeats previ-
ously described, thus adding new data supporting clinical practice and genetic counseling.
Our study suggests that the clinical categories in adulthood do not represent different stages of disease course 
but identify specific phenotypes, as the distribution of clinical categories is not strictly influenced by the age at 
examination. In the group of bDRA carriers the majority of patients with a classic FSHD phenotype showed 
an adult-onset form of disease with a moderate-severe degree of muscle impairment. Remarkably, cases with 
Table 4.  Penetrance of bDRA in families with 4 or more carriers.
Family ID Subjects with DRA (n)
Clinical category
Penetrance (%)Proband Relatives (n)
FSHD 1639 4 C1 C2 (3) 0
FSHD 219 5 A3 C2 (4) 20
FSHD 1779 5 A2 C (4) 20
FSHD 1011 4 D1 C2 (3) 25
FSHD 1722 4 D1 C2 (3) 25
FSHD 952 7 A3 D2 (1) C2 (5) 28
FSHD 135 9 A2 A2 (2) B1 (1) C (5) 45
FSHD 1239 4 B1 B1 (1) C (2) 50
FSHD 348 5 B1 B1 (2) C (2) 60
FSHD 1855 5 A2 D1 (1) D2 (1) C (2) 60
FSHD 1624 4 A3 A2 (2) D2 (1) 100
FSHD 1971 4 A2 B1 (2) D1 (1) 100
Figure 4.  Distribution of the clinical categories observed among relatives in 58 families in which a bDRA 
segregates according to the clinical category of index cases. The total number of families in each group is 
indicated, as well as the total number of individuals examined (n).
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facial-sparing phenotype, subcategory B1, had milder muscle impairment and have no relatives with classical 
FSHD phenotype. A similar observation has been recently reported in a cohort of Chinese patients and in FSHD 
patient population from the UK FSHD patient  registry36,43. Notably, in our recently published 5-year follow-up 
 study44 confirmed that clinical progression varies in people showing the different phenotypes described by the 
CCEF clinical categories. The distribution of clinical categories observed in subjects carrying a bDRA is also 
similar to those reported in our concomitant study conducted on cohort of 422 individuals carrying a DRA with 
7 to 8 D4Z4 repeats from  INFR13, thus highlighting that among carriers of D4Z4 reduced allele it is possible to 
recognize different clinical subgroups with distinct clinical features that need ad hoc studies.
In particular, the present study confirms the wide clinical variability among carriers of bDRA, highlighted 
by the fact that 46% of index cases do not show the classical FSHD phenotype with facial and shoulder girdle 
involvement. Remarkably, Table 3 shows that among atypical phenotypes, the prevalent clinical feature is the 
involvement of axial and pelvic muscles, which are features observed in several genetic and acquired myopathies. 
As an example, axial muscle weakness has been reported among carrier of  DRA45,46. However, it is also known 
that several muscle diseases, such as inflammatory myopathies, limb-girdle muscular dystrophies, congenital 
myopathies or metabolic myopathies, can primarily affect the axial muscles and produce bent spine  syndrome47.
Moreover, the finding of a family (Fig. 3) with several healthy carriers in which the only subject who devel-
oped after receiving anticancer treatments reinforces the idea that among carriers of bDRA disease may manifest 
itself through a multistep process. It is indeed possible that the bDRA constitutes a sensitizing condition that in 
presence of additional elements, genetic, epigenetic or environmental, favors the development of a myopathic 
phenotype affecting different muscles thus explaining the wide spectrum of clinical phenotypes.
Overall, this possibility is emphasized by the low penetrance of bDRA and by the fact that more than 70% of 
carrier relatives in our study show no motor impairment. In all these cases, family analysis (see example Fig. 3) 
adds crucial information.
Furthermore, as shown in Fig. 4, the analysis of intra-familial phenotypes and mode of inheritance can help 
to identify pedigrees in which alternative diagnosis must be considered or new genes can be searched.
Our study shows that in the group of carriers of bDRA the molecular marker is relevant neither for the 
diagnosis, all categories are represented, nor for the assessment of the genetic risk in relatives, overall 70.9% 
of relatives are healthy. Instead the distribution of the phenotypes within each family can provide information 
about the possible mechanism leading to disease. Genetic counseling should be guided by the extended clini-
cal investigation of the proband’s family. Families in which the pedigree analysis suggests mendelial models of 
inheritance should be investigated to find candidate genes responsible for disease. In isolated cases one should 
consider additional factors contributing to disease development.
Overall, the evidences reported by the Italian Clinical Network for FSHD highlight the need to consider a 
standardized assessment for the best clinical management, for selection of patients in testing genetic modifiers 
and for trial  readiness48.
Conclusions
Since we found that in our healthy control population 3.7% of subjects carry a bDRA, the detection of it should be 
consider as a genetic susceptibility condition rather than a diagnostic marker. Accordingly, our large cohort study 
confirmed that the diagnostic value of bDRA is poor and, therefore, the recurrence risk cannot be estimated.
Figure 5.  Proposal of a diagnostic flow chart for index cases with bDRA.
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We therefore recommend diagnostic procedures and genetic counseling to be based on clinical data and 
family studies (Fig. 5). In families in which the index case and at least one affected relative show the classical 
FSHD phenotype, the diagnosis of FSHD can be performed and the mode of inheritance (autosomal dominant? 
recessive? X-linked?) should be investigated; these families can be selected to further studies in order to search 
for additional genes/modifier/causative factors. In presence of atypical phenotypes and/or isolated cases with all 
healthy relatives it is not possible to perform conclusive diagnosis of FSHD. All these cases need further investiga-
tion, such as muscle biopsy, for a proper diagnosis or to investigate environmental factors or co-morbidities that 
may trigger the pathogenic process (Fig. 5). Nowadays different high-throughput sequencing approaches, such 
as Whole Genome Sequencing or Whole Exome Sequencing, are available for family studies aimed at identifying 
genetic factors, including molecular mosaicism, contributing to the clinical phenotype.
Our recommendations constitute the basis for stratification and definition of eligibility criteria for trial readi-
ness of cases in which a bDRA is detected.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon 
request.
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